StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
QSI$0.91+0.00%
Fair $0.91+0.0%

QSI

Quantum-Si incorporated

Healthcare / Medical DevicesNasdaqGM

$0.91

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.91Fund rank 27/100 · Data gapFallback financials|
SA 2/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 24%

FCF escenarios

weak_data · normalized FCF $-97.2M · quality 55.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 35/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

2/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 7Warnings: 1unknown: 7
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -46.0%, below the 5% threshold
Thesis & Journal · QSILocal privado en este navegador · Quantum-Si incorporated
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$197M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-46.0%

↓

Gross Margin

47.3%

↓

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2019–2025 · 6 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

-3991.5%

FCF / Net income

0.96x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.4M · net income $-101.3M · FCF $-97.2M

2019-FY → 2025-FY

Gross margin

47.3%— pts

Operating margin

-4766.0%— pts

Net margin

-4160.1%— pts

FCF margin

-3991.5%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
Income Statement
Revenue$2.4M$2.4M$3.1M$1.1M$0.00$0.00——
Net Income$-101.3M$-101.3M$-101.0M$-96.0M$-132.4M$-95.0M$-36.6M$-35.8M
EBITDA$-111.6M$-111.6M$-104.0M$-107.0M$-121.3M$-95.9M$-35.8M$-35.8M
EPS-0.51-0.51-0.71-0.68-0.95-1.19-6.84-6.95
Gross Margin47.3%47.3%52.3%45.1%————
Operating Margin-4766.0%-4766.0%-3550.6%-10274.6%————
Net Margin-4160.1%-4160.1%-3303.0%-8868.8%————
Cash Flow
Free Cash Flow$-97.2M$-97.2M$-92.4M$-98.5M$-101.3M$-72.6M$-33.0M$-31.9M
Returns
ROE-46.0%-46.0%-46.9%-35.3%-36.9%-19.9%22.9%28.6%
Growth & Yield
Revenue Growth-20.3%-20.3%182.6%—————
EPS Growth28.2%28.2%-4.4%28.4%20.2%82.6%1.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.